Compare BIO-TECHNE Corp (TECH) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs YieldMax Universe Fund of Option Income ETFs — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while YieldMax Universe Fund of Option Income ETFs trades at $7.7. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| TECH | YMAX | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $72.29 | $13.26 |
52-Week Low | $43.31 | $7.27 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
YMAX trades at $7.70, up 1.58% today, with a neutral technical signal and bearish moving averages. Recent news highlights weekly dividend distributions, though a 24/7 Wall Street article on July 14, 2026, notes shrinking payouts and a 1.33% fee structure. The stock lacks disclosed financial ratios, limiting fundamental clarity.
The outlook is mixed, with income appeal from dividends offset by fee concerns and opaque fundamentals. Risks include cost inefficiencies and reliance on market volatility for returns, while technicals suggest near-term consolidation around $8 support/resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
